CRVO · Insider Trading
CervoMed Inc. Common Stock
Every open-market purchase and sale reported by CRVO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Kelly Blackburn | EVP, Clinical Development | A | +19,100 deriv. | — |
| 2026-10-23 | Matthew Winton | Chief Commercial and Business | A | +19,100 deriv. | — |
| 2026-10-23 | Mark De Rosch | EVP, RA and GA and PgM | A | +19,100 deriv. | — |
| 2026-06-15 | Joshua S Boger | Director | Buy | +955,414 | +$3.00M |
| 2026-06-10 | Jeffrey V. Poulton | Director | A | +8,150 deriv. | — |
| 2026-06-10 | Sylvie Gregoire | Director | A | +8,150 deriv. | — |
| 2026-06-10 | John J Alam | CEO & President | A | +8,150 deriv. | — |
| 2026-06-10 | Joshua S Boger | Director | A | +8,150 deriv. | — |
| 2026-06-10 | Marwan Sabbagh | Director | A | +8,150 deriv. | — |
| 2026-06-10 | Frank Zavrl | Director | A | +8,150 deriv. | — |
| 2026-06-10 | David Quigley | Director | A | +8,150 deriv. | — |
| 2026-06-10 | Jane H Hollingsworth | Director | A | +8,150 deriv. | — |
| 2026-02-13 | Kelly Blackburn | EVP, Clinical Development | A | +30,000 deriv. | — |
| 2026-02-13 | Mark De Rosch | EVP, RA and GA and PgM | A | +30,000 deriv. | — |
| 2026-02-13 | Sylvie Gregoire | Director | A | +75,000 deriv. | — |
| 2026-02-13 | William Robert Elder | CFO, GC & Secretary | A | +30,000 deriv. | — |
| 2026-02-13 | Matthew Winton | Chief Commercial and Business | A | +30,000 deriv. | — |
| 2026-02-13 | John J Alam | CEO & President | A | +75,000 deriv. | — |
| 2025-12-05 | David Quigley | Director | A | +16,200 deriv. | — |
| 2025-11-19 | Sylvie Gregoire | Director | Buy | +21,600 | +$182.74K |
| 2025-11-19 | Matthew Winton | Chief Commercial and Business | Buy | +5,000 | +$41.43K |
| 2025-11-19 | William Robert Elder | CFO, GC & Secretary | Buy | +3,500 | +$29.25K |
| 2025-11-19 | John J Alam | CEO & President | Buy | +21,600 | +$182.74K |
| 2025-11-17 | Matthew Winton | Chief Commercial and Business | Buy | +10,000 | +$75.70K |
| 2025-11-17 | John J Alam | CEO & President | Buy | +7,847 | +$59.10K |
| 2025-11-17 | Sylvie Gregoire | Director | Buy | +7,847 | +$59.10K |
| 2025-11-13 | Sylvie Gregoire | Director | Buy | +5,553 | +$40.81K |
| 2025-11-13 | John J Alam | CEO & President | Buy | +5,553 | +$40.81K |
| 2025-11-13 | William Robert Elder | CFO, GC & Secretary | Buy | +3,500 | +$26.04K |
| 2025-10-08 | Matthew Winton | Chief Commercial and Business | A | +75,000 deriv. | — |
| 2025-06-25 | John J Alam | CEO & President | A | +8,100 deriv. | — |
| 2025-06-25 | Marwan Sabbagh | Director | A | +8,100 deriv. | — |
| 2025-06-25 | Joshua S Boger | Director | A | +8,100 deriv. | — |
| 2025-06-25 | Jeffrey V. Poulton | Director | A | +8,100 deriv. | — |
| 2025-06-25 | Jane H Hollingsworth | Director | A | +8,100 deriv. | — |
| 2025-06-25 | Sylvie Gregoire | Director | A | +8,100 deriv. | — |
| 2025-06-25 | Frank Zavrl | Director | A | +8,100 deriv. | — |
| 2025-05-14 | William Robert Elder | CFO, GC & Secretary | Buy | +4,233 | +$35.81K |
| 2025-02-14 | William Robert Elder | CFO & GC | A | +27,000 deriv. | — |
| 2025-02-14 | John J Alam | CEO & President | A | +60,000 deriv. | — |
| 2025-02-14 | Robert Joseph Cobuzzi Jr. | Chief Operating Officer | A | +27,000 deriv. | — |
| 2025-02-14 | Kelly Blackburn | SVP, Clinical Development | A | +27,000 deriv. | — |
| 2025-02-14 | Sylvie Gregoire | Director | A | +60,000 deriv. | — |
| 2024-08-27 | William Robert Elder | CFO & GC | Buy | +1,000 | +$18.16K |
| 2024-06-14 | John J Alam | CEO & President | A | +5,750 deriv. | — |
| 2024-06-14 | Frank Zavrl | Director | A | +5,750 deriv. | — |
| 2024-06-14 | Marwan Sabbagh | Director | A | +5,750 deriv. | — |
| 2024-06-14 | Jeffrey V. Poulton | Director | A | +5,750 deriv. | — |
| 2024-06-14 | Sylvie Gregoire | Director | A | +5,750 deriv. | — |
| 2024-06-14 | Jane H Hollingsworth | Director | A | +5,750 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joshua S Boger | Director | 2,012,682 | $3.14M |
| John J Alam | CEO & President | 1,496,578 | $2.33M |
| Sylvie Gregoire | Director | 1,496,578 | $2.33M |
| Matthew Winton | Chief Commercial and Business | 15,000 | $23.40K |
| William Robert Elder | CFO, GC & Secretary | 12,500 | $19.50K |
| Jane H Hollingsworth | Director | 943 | $1.47K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRVO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.